血液系统疾病中的分子免疫学。
Molecular Immunology in Hematological Disorders.
机构信息
Department of Medicine, Division of Hematology, Aichi Medical University School of Medicine, Nagakute 480-1195, Japan.
出版信息
Int J Mol Sci. 2022 Aug 24;23(17):9584. doi: 10.3390/ijms23179584.
Abstract
This Special Issue aims to highlight the molecular mechanisms involved in the development and progression of hematologic malignancies such as leukemia, lymphoma, and myeloma [...].
摘要
本期特刊旨在强调血液系统恶性肿瘤（如白血病、淋巴瘤和骨髓瘤等）的发展和进展所涉及的分子机制。
相似文献
1
Molecular Immunology in Hematological Disorders.
Int J Mol Sci. 2022 Aug 24;23(17):9584. doi: 10.3390/ijms23179584.
2
[Review of relationship between tumor necrosis factor genetic polymorphism and hematological malignancies].
Ai Zheng. 2003 Feb;22(2):216-20.
3
B-cell maturation antigen expression across hematologic cancers: a systematic literature review.
Blood Cancer J. 2020 Jun 30;10(6):73. doi: 10.1038/s41408-020-0337-y.
4
Familial (inherited) leukemia, lymphoma, and myeloma: an overview.
Blood Cells Mol Dis. 2004 Jan-Feb;32(1):246-61. doi: 10.1016/j.bcmd.2003.10.005.
5
The Role of RNA-Binding Proteins in Hematological Malignancies.
Int J Mol Sci. 2022 Aug 23;23(17):9552. doi: 10.3390/ijms23179552.
6
Cytogenetic and FISH studies in myelodysplasia, acute myeloid leukemia, chronic lymphocytic leukemia and lymphoma.
Int J Hematol. 2002 Aug;76 Suppl 2:65-74. doi: 10.1007/BF03165090.
7
[Advances in the target therapy of hematological malignancies].
Sichuan Da Xue Xue Bao Yi Xue Ban. 2014 Jul;45(4):642-6.
8
Integrative oncogenomic analysis of microarray data in hematologic malignancies.
Methods Mol Biol. 2010;576:231-77. doi: 10.1007/978-1-59745-545-9_13.
9
Absence of BRAF V600E mutation in hematologic malignancies excluding hairy-cell leukemia.
Leuk Lymphoma. 2012 Dec;53(12):2498-9. doi: 10.3109/10428194.2012.695777. Epub 2012 Jul 9.
10
[p53 and hematologic malignancies].
Pathol Biol (Paris). 1997 Dec;45(10):898-908.
本文引用的文献
1
The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches.
Int J Mol Sci. 2022 May 8;23(9):5242. doi: 10.3390/ijms23095242.
2
Acute Neurological Involvement after Donor Lymphocyte Infusion for Post-Transplant Viral Infection: The Same Pattern of Novel Cancer Immunotherapy-Related CNS Toxicity?
Int J Mol Sci. 2022 Mar 24;23(7):3553. doi: 10.3390/ijms23073553.
3
Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination.
Int J Mol Sci. 2022 Mar 19;23(6):3338. doi: 10.3390/ijms23063338.
4
The Impact of NLRP3 Activation on Hematopoietic Stem Cell Transplantation.
Int J Mol Sci. 2021 Oct 31;22(21):11845. doi: 10.3390/ijms222111845.
5
Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma.
Int J Mol Sci. 2021 Oct 5;22(19):10761. doi: 10.3390/ijms221910761.
6
Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia.
Int J Mol Sci. 2021 Aug 25;22(17):9159. doi: 10.3390/ijms22179159.
7
Donor UNC-93 Homolog B1 genetic polymorphism predicts survival outcomes after unrelated bone marrow transplantation.
Genes Immun. 2021 May;22(1):35-43. doi: 10.1038/s41435-021-00122-y. Epub 2021 Feb 24.
8
Donor Heme Oxygenase-1 Promoter Gene Polymorphism Predicts Survival after Unrelated Bone Marrow Transplantation for High-Risk Patients.
Cancers (Basel). 2020 Feb 12;12(2):424. doi: 10.3390/cancers12020424.
9
Role of alternative donor allogeneic hematopoietic stem cell transplantation in patients with intermediate- or poor-risk acute myeloid leukemia in first complete remission.
Bone Marrow Transplant. 2019 Dec;54(12):2004-2012. doi: 10.1038/s41409-019-0571-8. Epub 2019 May 31.
10
Recipient Single-Nucleotide Polymorphism Predicts Relapse after Unrelated Bone Marrow Transplantation for Hematologic Malignancy.
Int J Mol Sci. 2019 Jan 8;20(1):214. doi: 10.3390/ijms20010214.
Zotero 插件